All In Biotech

Drug Trial Radar · NCT00459667

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

International, Multicenter, Phase IIIb Study of Subcutaneous Every-other-day Treatment of Patients With Relapsing Multiple Sclerosis With (Phase A): Double-blind Betaseron/Betaferon 250µg or 500µg or Open-label Betaseron/Betaferon 250µg and (Phase B): Open-label Betaseron/Betaferon 500µg

Last checked: Nov 20, 2026Latest source record: Apr 23, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,420

Actual

Start

May 2007

Primary completion

Mar 2008

Study completion Mar 2008

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Apr 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and tolerability profile of interferon beta 1b 500µg during longer-term treatment.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

  • Interferon beta-1b (Betaseron, BAY86-5046)Drug

    Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).

  • Interferon beta-1b (Betaseron, BAY86-5046)Drug

    Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).

  • Interferon beta-1b (Betaseron, BAY86-5046)Drug

    Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162. Phase B: All patients will receive 500µg s.c.every other day (open-label).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Flu-like-syndromeTime frame: 309 days
  2. Injection-site ReactionsTime frame: 309 days
  3. Liver Enzyme ElevationsTime frame: 309 days
  4. Hematological AbnormalitiesTime frame: 309 days

Locations

184 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Cullman, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Berkeley, California

  • Site not named

    La Jolla, California

  • Site not named

    Sacramento, California

  • Site not named

    San Francisco, California

  • Site not named

    Fort Collins, Colorado

  • Site not named

    Newark, Delaware

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Maitland, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Fort Wayne, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Des Moines, Iowa

  • Site not named

    Kansas City, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Detroit, Michigan

  • Site not named

    Duluth, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Henderson, Nevada

  • Site not named

    Reno, Nevada

  • Site not named

    Newark, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Mineola, New York

  • Site not named

    Rochester, New York

  • Site not named

    Stony Brook, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Tualatin, Oregon

Showing 40 of 184 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.